ArticleScientific reports2022
Long-term persistence of treatment after hip fracture in a fracture liaison service.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Primary care follow-up of patients after attending a fracture liaison service: an integrative review.Archives of osteoporosis · 2025Pooled it
- The impact of a fracture liaison service for patients with femoral fractures on subsequent fractures and mortality: focusing on systematic literature review and metaanalysis.Archives of osteoporosis · 2025Pooled it
- Article
- A territorially coordinated, eHealth-supported fracture liaison service following femur fragility fracture: a pilot randomised controlled trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- The Critical Role of Follow-Up in Fracture Liaison Services for Geriatric Hip Fracture Patients: A Retrospective Cohort Study.Geriatric orthopaedic surgery & rehabilitation · 2026Article
- Development of a prediction model for recurrent vertebral fractures in patients two years after vertebral augmentation using noninvasive data: a retrospective study.BMC musculoskeletal disorders · 2025Article
- Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Observational
- Effects of introducing a new reimbursement scheme on pharmaceutical treatment for osteoporosis after hip fracture.Journal of bone and mineral metabolism · 2025Article
- The impact of in-hospital initiation of a surgeon-led, anti-osteoporotic medication algorithm for patients with fragility hip fractures: a quasi-experimental study.Archives of orthopaedic and trauma surgery · 2025Article
- Impact of the FLS model on patients with major fracture in Gran Canaria: 2018-2022 experience.Archives of osteoporosis · 2025Article
- Prognostic Factors of Hip Fracture in Elderly: A Systematic Review.International journal of preventive medicine · 2024Review
- Exploring barriers and opportunities to improve osteoporosis care across the acute-to-primary care interface: a qualitative study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Article
- Active identification of vertebral fracture in the FLS model of care.Archives of osteoporosis · 2023Observational
- The role of the fracture liaison service in the prevention of atypical femoral fractures.Therapeutic advances in musculoskeletal disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Patients ≥ 50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identification mode, previous treatment and FRAX items. Patient records were reviewed 3-8 years later, and these data were collected: (1) survival; (2) major refracture; (3) initiation of treatment, proportion of days covered (PDC) and persistence with AOM. 372 patients (mean age, 79 years; 76% women) were included. Mean follow-up was 47 months, 52 patients (14%) had a refracture (22 hip) and 129 (34.5%) died. AOM was started in 283 patients (76.0%). Factors associated with initiation of AOM were previous use of bisphosphonate (OR 9.94; 95% CI 1.29-76.32) and a lower T-score lumbar (OR 0.80; 95% CI 0.65-0.99). Persistence decreased to 72.6%, 60% and 47% at 12, 36 and 60 months. A PDC > 80% was confirmed in 208 patients (55.7%) and associated with previous use of bisphosphonate (OR 3.38; 95% CI 1.34-8.53), treatment with denosumab (OR 2.69; 95% CI:1.37-5.27), and inpatient identification (OR 2.26; 95% CI 1.18-4.34). Long-term persistence with AOM was optimal in patients with hip fracture seen at an FLS. A PDC > 80% was associated with inpatient identification and prescription of denosumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.